Emtricitabine
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
- Emtricitabine
- Pharmacist Assessment Report
- Emtricitabine: From HIV Infection to Feline Acquired Immunodeficiency Syndrome
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Emtricitabine: From HIV Infection to Feline Acquired Immunodeficiency Syndrome
One-Sentence Summary
Emtricitabine is a nucleoside reverse transcriptase inhibitor originally used to treat HIV infection and AIDS. The TxGNN model predicts it may be effective for feline acquired immunodeficiency syndrome (FIV), but there are 0 clinical trials and only 1 publication (a veterinary study whose design could not be verified) behind this top-ranked prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | HIV infectious disease; AIDS |
| Predicted New Indication | Feline acquired immunodeficiency syndrome |
| TxGNN Prediction Score | 0.9992 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs on record: at least 20) |
| Number of DINs | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI), and its efficacy in HIV-1 infection is established. Mechanistically, it may be applicable to feline immunodeficiency virus.
FIV is a lentivirus related to HIV. It causes progressive immune dysfunction in cats, much like HIV in humans, and it also depends on reverse transcriptase to replicate. NRTI activity against it is therefore biologically plausible.
The very high TxGNN score (0.9992) mostly reflects how similar this disease is to HIV, not independent clinical evidence. This prediction is also veterinary, so it is not a new human indication.
The second-ranked prediction, simian immunodeficiency virus (SIV) infection, has more supporting literature. These are mostly macaque studies in which emtricitabine, usually combined with tenofovir, prevented or suppressed SHIV infection. They validate the existing HIV mechanism in animal models rather than opening a new human indication. The third-ranked prediction, a rare neurodevelopmental disorder with ataxic gait, absent speech and decreased cortical white matter, has no plausible mechanistic link, no trials and no literature. It should be treated as a likely false positive.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
For the top-ranked prediction (FIV):
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 37112803 | 2023 | Preclinical/veterinary study (design not verified) | Viruses | Evaluated pharmacokinetics and clinical outcomes of combination antiretroviral therapy (dolutegravir, tenofovir, emtricitabine) in FIV-infected domestic cats |
For the second-ranked prediction (SIV infection), selected preclinical publications:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 27465645 | 2016 | Preclinical animal study | J Infect Dis | Oral emtricitabine/tenofovir alafenamide protected macaques from rectal SHIV infection |
| 31362305 | 2019 | Preclinical animal study | J Infect Dis | Oral TAF/emtricitabine or TAF alone tested against vaginal SHIV infection in macaques |
| 26743846 | 2016 | Preclinical animal study | J Infect Dis | Emtricitabine/TDF prevented vaginal SHIV infection in macaques with Chlamydia and Trichomonas coinfection |
| 39632836 | 2024 | Preclinical animal study | Nat Commun | Early treatment with emtricitabine/TAF plus long-acting cabotegravir/rilpivirine achieved SHIV remission in macaques |
| 24914761 | 2014 | Preclinical animal study | AIDS Res Hum Retroviruses | HIV vaccine combined with partially protective oral PrEP prevented SHIV infection in macaques |
| 12021341 | 2002 | Preclinical virology study | J Virol | M184V resistance mutation emerged within 5 weeks of lamivudine or emtricitabine treatment in SIV-infected newborn macaques, with reduced viral fitness |
| 22964889 | 2012 | Review | Curr Opin HIV AIDS | Lessons from animal models of antiretroviral PrEP |
| 20874040 | 2010 | Review | Pharmacotherapy | Review of systemic pre-exposure prophylaxis for HIV |
| 22918448 | 2012 | Review/Commentary | Curr Opin HIV AIDS | Considerations for antiretroviral chemoprophylaxis in men who have sex with men |
| 22814162 | 2012 | Preclinical animal study | Jpn J Infect Dis | Double oral dose of emtricitabine/tenofovir before exposure protected macaques against highly pathogenic SHIV |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02274906 | TRUVADA | Not specified | Not specified |
| 02454424 | DESCOVY | Not specified | Not specified |
| 02478579 | BIKTARVY | Not specified | Not specified |
| 02374129 | COMPLERA | Not specified | Not specified |
| 02473720 | SYMTUZA | Not specified | Not specified |
All 20 licences are valid. Many are generic emtricitabine/tenofovir or efavirenz/emtricitabine/tenofovir combination products.
Safety Considerations
Contraindication signals from the knowledge graph (not label text): these include liver failure, liver disease, kidney disease, chronic hepatitis B and C virus infection, lactic acidosis, Fanconi renotubular syndrome, hypophosphatemia, osteomalacia, rickets, long QT syndrome and torsades de pointes, fatty liver disease, non-alcoholic steatohepatitis, hypertriglyceridemia, epilepsy, and several psychiatric conditions (anxiety, dysthymic, delusional disorders, paranoid schizophrenia). Several of these probably come from combination partner drugs, so they should be verified against the package insert.
Drug Interactions (20 recorded):
- Major: leflunomide, teriflunomide
- Moderate: orlistat, naltrexone, cobicistat, asparaginase, interferon beta-1a/1b, peginterferon beta-1a, brentuximab vedotin, cabozantinib, cladribine, clofarabine, epirubicin, idelalisib, methotrexate, pegaspargase, tioguanine, trabectedin
- Minor: eribulin
Package insert warnings and contraindications from Health Canada were not available, so please refer to the package insert for authoritative safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction (FIV) is veterinary and rests on a single study of unverified design, with no clinical trials. The SIV evidence is solid but preclinical, and it supports the existing HIV indication rather than a new human one. The third prediction has no supporting evidence at all.
To proceed, the following is needed:
- Mechanism of action data for emtricitabine
- Health Canada package insert warnings and contraindications
- Verification of the FIV study’s design and outcomes, and a decision on whether a veterinary indication is within scope
- A plausible biological rationale for the neurodevelopmental disorder prediction, or its removal as a likely false positive
- If a human indication is the goal, a review of other predicted indications beyond these top three
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.